Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Novel biological therapies for managing non-Hodgkin lymphoma

Martin Dreyling • 5 Dec 2014
ASH 2014
Non-Hodgkin Lymphoma Lenalidomide

Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel biological therapies for the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

More from Martin Dreyling

TRIANGLE: ibrutinib with standard treatment or without autoHSCT in younger patients with MCL
7:56
TRIANGLE: ibrutinib with standard treatment or without autoHSCT in younger patients with MCL
Martin Dreyling • 10 Dec 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals